NCT02288533

Brief Summary

Chronic consciousness disorders have high level of impact on public health and its costs.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
10

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Sep 2014

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 16, 2014

Completed
8 months until next milestone

Study Start

First participant enrolled

September 1, 2014

Completed
2 months until next milestone

First Posted

Study publicly available on registry

November 11, 2014

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2016

Completed
Last Updated

February 3, 2017

Status Verified

February 1, 2017

Enrollment Period

2.2 years

First QC Date

January 16, 2014

Last Update Submit

February 2, 2017

Conditions

Keywords

Minimally Conscious StatetDCS

Outcome Measures

Primary Outcomes (1)

  • Coma Recovery Scale Revised (CRS-R)

    behavioural scale (visual, auditory, motor, verbal, communication, arousal)

    Change measures (weeks: -2,0,1,2,4)

Secondary Outcomes (4)

  • single-pulse transcranial magnetic stimulation (TMS)

    Change measures (weeks: -2,0,1,2,4)

  • functional near infrared spectroscopy (fNIRS)

    Change measures (weeks: -2,0,1,2,4)

  • electroencephalography (EEG)

    Change measures (weeks: -2,0,1,2,4)

  • Circulating Biomarkers

    Change measures (weeks: -2,0,1,2,4)

Study Arms (1)

real-tDCS

EXPERIMENTAL

Participants will receive tDCS over the primary motor cortex bilaterally (M1). The excitability-enhancing anode electrode (saline-soaked sponge electrode - 16cm2) will be placed over the primary motor cortex, C3 and C4 (10/20 international EEG system). The excitability-diminishing cathode electrode will be placed over the supraorbital area. We will use the following stimulation parameters: intensity of 2 milliampere and for 40 minutes (10 consecutive sessions).

Device: real-tDCS

Interventions

real-tDCSDEVICE

Participants will receive tDCS over the primary motor cortex bilaterally (M1). The excitability-enhancing anode electrode (saline-soaked sponge electrode - 16cm2) will be placed over the primary motor cortex, C3 and C4 (10/20 international EEG system). The excitability-diminishing cathode electrode will be placed over the supraorbital area. We will use the following stimulation parameters: intensity of 2 milliampere and for 40 minutes (10 consecutive sessions).

real-tDCS

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • males and females aged \>18 years old and \<70 years old
  • diagnosis of disorders of consciousness classified as MCS according to criteria of American Academy of Neurology1.
  • traumatic etiology (\>12 months after the acute injury)

You may not qualify if:

  • contraindications to single pulse TMS (TMS will be used to measure cortical excitability) such as metal head implants, history of seizures, metal in the head, implanted brain medical devices.
  • contraindications to tDCS such as metal in the head, implanted brain medical devices.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ferrara University Hospital

Ferrara, Italy, Italy

Location

MeSH Terms

Conditions

Persistent Vegetative State

Condition Hierarchy (Ancestors)

Brain Damage, ChronicBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesUnconsciousnessConsciousness DisordersNeurobehavioral ManifestationsNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Sofia Straudi, MD

    Ferrara Rehabilitation Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
OTHER
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD

Study Record Dates

First Submitted

January 16, 2014

First Posted

November 11, 2014

Study Start

September 1, 2014

Primary Completion

November 1, 2016

Study Completion

November 1, 2016

Last Updated

February 3, 2017

Record last verified: 2017-02

Data Sharing

IPD Sharing
Will not share

Locations